Venkys (India) Ltd Q2 FY26 Results & Concall Highlights: Revenue, Margins & Order Book
Published 28 May 2026 | Food Products | Market Cap: ₹2.2K Cr
Animal Health segment is expected to grow steadily, aiming to cross INR 370-380 crores this year with new product lines planned, indicating stable and consistent growth. Poultry segment losses are significant currently but improvement expected in second half of FY '26 due to better realizations and demand post-festive season.
From Venkys (India) Ltd's Q2 FY26 earnings-call transcript · updated 23 Aug 2026.
Price
₹1,507
Market Cap
₹2.2K Cr
P/E Ratio
12.4
How does Venkys (India) Ltd rank in Food Products?
Compare Venkys (India) Ltd against every Food Products company this quarter on revenue, margins and earnings-call signals.
Venkys (India) Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest: revenue ₹1.1K Cr, net profit ₹101 Cr.
Full financials →📊 Revenue & Sales Performance
- →Animal Health segment is expected to grow steadily, aiming to cross INR 370-380 crores this year with new product lines planned, indicating stable and consistent growth.
- →Poultry segment volume utilization currently at 67% (broiler) and 75% (layer), with capacity available to increase production by about 25-33% if demand improves.
- →Expansion plans are underway for the SPF segment post-rainy season and possible layer segment expansion in FY 27-28, indicating future capacity increase.
- →Poultry prices expected to improve from January to June, supporting volume and revenue growth.
- →Raw material costs expected to stabilize with possible positive impact on margins in coming quarters.
- →Overall volumes and revenue growth are tied closely to market demand, seasonal factors, and price realizations; improvement anticipated in the second half of FY 26 and beyond.
📈 Profitability & Margins
🏗️ Capital Expenditure Plans
- →Expansion plans underway in the SPF (Specific Pathogen Free) segment, with capacity buildup expected to start after the rainy season.
- →Capacity expansion has already taken place in the Animal Health Products (AHP) segment.
- →Plans for poultry segment expansion, particularly in the layer segment, are being considered for fiscal years 2027-28.
- →Current capacity and numbers are deemed sufficient to meet market requirements for now.
- →No specific mention of new strategic investments beyond these expansions was provided.
💰 Fundraising & Capital Structure
- →There is no mention of any current or planned fundraising through debt or equity in the transcript.
- →The management did not discuss raising capital or issuing new shares during the Q2 FY '26 earnings call.
- →Expansion plans discussed are primarily focused on capacity buildup in SPF, AHP, and layer segments without reference to new funding.
- →No specific updates on debt refinancing or equity dilution were provided.
- →For any unanswered questions, including fundraising plans, investors are encouraged to email the company’s investor relations.
📋 Order Book & Pipeline
Key Metrics
Frequently Asked Questions
What were Venkys (India) Ltd Q2 FY26 results?
Animal Health segment is expected to grow steadily, aiming to cross INR 370-380 crores this year with new product lines planned, indicating stable and consistent growth. Poultry segment losses are significant currently but improvement expected in second half of FY '26 due to better realizations and demand post-festive season.
What is Venkys (India) Ltd share price analysis?
Venkys (India) Ltd currently shows a neutral. The stock trades at a P/E of 12.4 with a market cap of ₹2,153 Cr. Investors should review the full earnings analysis for detailed insights.
Is Venkys (India) Ltd planning capital expenditure?
Expansion plans underway in the SPF (Specific Pathogen Free) segment, with capacity buildup expected to start after the rainy season.
Keep Venkys (India) Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and concall transcripts. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.
